Crain’s Cleveland Business: Lamassu Biotech expanding corporate offices to Cleveland

05/21/2024

A North Carolina biotech research firm is expanding its novel therapeutic and drug development efforts to Cleveland.

Lamassu Biotech said it’s launching corporate offices in the city. The company is collaborating with Cleveland Clinic as it gears up to launch a phase 1/2a clinical trial for a genetically targeted oncology program that would offer an alternative to invasive therapies. 

CLICK HERE to read the full story from Crain’s Cleveland Business.

READ MORE

06/06/2025

Crain’s Cleveland Business: Cleveland biotech company secures $2.7M in NIH funding

Lamassu Biotech, a company with its “second headquarters” in Cleveland, has received a $2.7 million grant from the National Institutes of Health (NIH). The funds will help support the development of a novel treatment protocol for acute pancreatitis in canines....

READ THE ARTICLE
06/04/2025

Cleveland Business Journal: Lamassu Biotech’s dog treatment could lead to human pancreatitis breakthrough, backed by NIH funds

Lamassu Biotech, the North Carolina-based biopharmaceutical company that opened a Cleveland office last year, has received a $2.7 million grant from the National Institutes of Health to help develop its therapy for dogs with acute pancreatitis. The therapeutic, called RABI-767, also could...

READ THE ARTICLE
04/08/2025

The Washington Times: Biotech should take a page from Elon Musk’s playbookThe Washington Post:

Innovation has always been the foundation of progress, but how we innovate matters as much as the results we achieve. Recent breakthroughs in aerospace and artificial intelligence prove that massive budgets don’t drive innovation, but efficiency, speed and a relentless...

READ THE ARTICLE